Shareholders' Equity

6 Months Ended

Jun. 30, 2015

Equity [Abstract]

Shareholders' Equity

Shareholders’ Equity

A summary of the changes in shareholders’ equity for the six months endedJune 30, 2015 and 2014 is as follows:

(In millions)	Total Mylan N.V. Shareholders' Equity			Noncontrolling Interest			Total
December 31, 2014	$	3,255.9		$	20.1		$	3,276.0
Net earnings	224.4			0.1			224.5
Other comprehensive loss, net of tax	(364.6		)	—			(364.6		)
Stock option activity	86.5			—			86.5
Share-based compensation expense	50.3			—			50.3
Issuance of restricted stock, net of shares withheld	(36.6		)	—			(36.6		)
Tax benefit of stock option plans	48.0			—			48.0
Issuance of ordinary shares to purchase the EPD Business	6,305.8			—			6,305.8
Purchase of subsidiary shares from noncontrolling interest	—			(18.7		)	(18.7		)
Other	(1.8		)	(0.1		)	(1.9		)
June 30, 2015	$	9,567.9		$	1.4		$	9,569.3

(In millions)	Total Mylan N.V. Shareholders' Equity			Noncontrolling Interest			Total
December 31, 2013	$	2,941.8		$	18.1		$	2,959.9
Net earnings	241.1			2.1			243.2
Other comprehensive earnings, net of tax	87.4			—			87.4
Stock option activity	29.9			—			29.9
Share-based compensation expense	32.5			—			32.5
Issuance of restricted stock, net of shares withheld	(20.2		)	—			(20.2		)
Tax benefit of stock option plans	21.5			—			21.5
Other	—			(1.5		)	(1.5		)
June 30, 2014	$	3,334.0		$	18.7		$	3,352.7

On February 27, 2015, Abbott transferred the EPD Business to Mylan N.V. in exchange for 110 million ordinary shares of Mylan N.V. As a result of the EPD Transaction, Mylan Inc. became an indirect wholly owned subsidiary of Mylan N.V.Mylan Inc.’s outstanding common stock, par value $0.50 per share, was exchanged on a one to one basis for Mylan N.V. ordinary shares, nominal value €0.01 per ordinary share. Immediately prior to the EPD Transaction, each share of Mylan Inc. common stock held in treasury was eliminated and the total recorded amount was reclassified as additional paid-in-capital.

On April 3, 2015, the Company and Stichting Preferred Shares Mylan (the “Foundation”) entered into a call option agreement (the “Call Option Agreement”). Pursuant to the terms of the Call Option Agreement, Mylan N.V. granted the Foundation a call option (the “Option”), permitting the Foundation to acquire from time-to-time Mylan N.V. preferred shares up to a maximum number equal to the total number of Mylan N.V. ordinary shares issued at such time to the extent such shares are not held by the Foundation. The exercise price of the Option is €0.01 per preferred share. On April 21, 2015, the Company received a letter from the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. ("Teva"), containing a non-binding expression of interest from Teva to acquire Mylan for $82 per Mylan ordinary share. On July 23, 2015, in response to Teva's unsolicited expression of interest in acquiring Mylan, the Foundation exercised the Option and acquired 488,388,431 Mylan preferred shares (which represents 100% of the class of Mylan preferred shares as of the date of this report) pursuant to the terms of the Call Option Agreement. Each Mylan ordinary share and preferred share is entitled to one vote on each matter properly brought before a general meeting of shareholders. On July 27, 2015, Teva announced its entry into an agreement to acquire the Generic Drug Unit of Allergan plc and the withdrawal of its unsolicited, non-binding expression of interest to acquire Mylan. If the Foundation determines that the perceived threat to Mylan and its stakeholders has been removed or sufficiently mitigated or neutralized, the Company expects that, as a matter of Dutch law and the Foundation's limited protective purpose, the Foundation will require Mylan to cancel its preferred shares.